Obesity

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Financial Aspect

Financial Aspect

Call for overhaul of drug industry business model.  Full Article 

Medical Decision

Medical Decision

U.S. doctor group votes to recognize obesity as a disease.  Full Article 

Swine Flu

Swine Flu

Outbreak of deadly piglet virus spreads to 13 U.S. states.  Full Article 

Breast Feeding

Breast Feeding

Venezuela considers taking bottles from babies' mouths.  Full Article 

E-cigarettes

E-cigarettes

Insight: No smoke, plenty of fire fuels e-cigarettes  Full Article 

New Diet

New Diet

New diet craze offers five days of feasting for two days of famine  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro

Related Topics

Stocks

   
A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

LEVERKUSEN, Germany | Wed Nov 14, 2012 3:17pm IST

LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

(Reporting by Frank Siebelt; Writing by Ludwig Burger)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.